idiopathic central precocious puberty.
Conditions
Interventions
Intervention group: Diferelin and Variopeptyle group :All girls with idiopathic central precocious puberty (ICPP) are included in the study. At the beginning of the study, their clinical and paraclini
Sponsors
Varianpharmed company
Eligibility
Sex/Gender
Female
Age
6 Years to 9 Years
Inclusion criteria
Inclusion criteria: Girls who started menstruating before the age of 9 Patients with a diagnosis of precocious puberty who have been previously treated with another GnRH analog compound and who have now stopped showing clinical signs of puberty. Advanced bone age by one year beyond chronological age Signed informed consent form No heart disease with a normal EKG
Exclusion criteria
Exclusion criteria: Sensitivity to drugs, especially GnRH agonists Central precocious puberty with a specific cause such as tumor, irradiation, etc. Those receiving growth hormone, thyroid drugs, and other drugs involved in the growth and maturation process. Those suspected of having malignant tumors Non-gonadotropin-dependent precocious puberty Any chronic diseases that interfere with growth, such as chronic steroid use, renal failure, and moderate to severe scoliosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sex hormones. Timepoint: befor study and month 3 and 6 and 9. Method of measurement: laboratory test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Breast and uterine and ovarian sonography. Timepoint: befor study and months 3 and 6 and 9. Method of measurement: ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShervin Fatehi ghahfarokhi
Iran University of Medical Sciences
Outcome results
None listed